Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences has announced positive data from a 48-week, multicenter, prospective, open-label Phase III clinical trial evaluating virologically-suppressed patients with HIV who switched from treatment with twice-daily Combivir to treatment with Gilead's once-daily Truvada as part of their combination drug therapy.
Subscribe to our email newsletter
In the SWEET (simplification with easier emtricitabine and tenofovir) study, patients who switched from Combivir to Truvada, both in combination with once-daily Sustiva (efavirenz), experienced improvements in a number of treatment-related side effects. Patients in both study arms maintained virological suppression at 48 weeks.
Martin Fisher, Brighton and Sussex University Hospitals, Brighton, UK and the principal investigator for the SWEET study, said: “As HIV patients live longer and remain on therapy for extended periods of time, the long-term side effect profile of treatment is increasingly more important. Data from this study indicate that patients on long-term Combivir therapy without clinical lipoatrophy may benefit from switching to Truvada, as virological control can be maintained and limb fat loss and recovery may be improved. These data support the new EACS 2007 guidelines regarding proactive switching.”